Every material Form 8-K CVS Health filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CVS Health announced its intention to separate into two independent, publicly traded companies in a transaction intended to be tax-free to the company and shareholders. The separation is expected to be completed in the first half of 2028, subject to customary conditions, and the company also announced third quarter 2026 results and raised its full-year 2026 guidance in a separate release.
Healthcare solutions company (CVS Health) would include Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health; David Joyner would be Chairman and CEO.
CVS Pharmacy would include about 9,000 CVS pharmacies, mail pharmacy, MinuteClinic and Health100; Prem Shah would be CEO.
Separation expected to be completed in the first half of 2028, subject to Board approval, effectiveness of a Form 10 registration statement and tax confirmation.
Company raised full-year 2026 guidance in a separate press release issued the same day; the amount of the raise is not stated in this filing.
CVS Health Corporation announced its third quarter 2026 financial results, reporting total revenues of $108.4 billion and a net income of $2.17 billion. Driven by strong performance across its Health Care Benefits and Pharmacy & Consumer Wellness segments, the company raised its full-year 2026 guidance.
Third quarter total revenues increased 5.4% year-over-year to $108.4 billion.
GAAP diluted EPS was $1.68 and Adjusted EPS was $2.09 for the third quarter of 2026.
Full-year 2026 GAAP diluted EPS guidance was raised to at least $6.98, and Adjusted EPS guidance was raised to at least $8.20.
Year-to-date cash flow from operations reached $15.3 billion as of September 30, 2026.
CVS Health appointed Teresa Heitsenrether, Executive Vice President and Chief Data & Analytics Officer at JPMorgan Chase, to its Board of Directors, effective November 18, 2026. Larry Robbins resigned from the Board effective August 13, 2026, and the company said his resignation was not due to any disagreement with the company. The filing reports no financial results, so the change is a board composition update rather than a change to company performance.
Teresa Heitsenrether joins the Board effective November 18, 2026, and was determined to be independent under NYSE rules.
Larry Robbins resigned from the Board effective August 13, 2026, after serving since 2024.
Heitsenrether's director compensation will match other non-employee directors, prorated for her start date.
CEO David Joyner said Heitsenrether brings experience in data, analytics and technology.
CVS Health reported second-quarter 2026 GAAP diluted EPS of $2.31, up from $0.80 a year earlier, and Adjusted EPS of $2.58, up from $1.81. The company raised its full-year 2026 GAAP EPS, Adjusted EPS and cash flow from operations guidance, citing the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the rest of the year due to elevated cost trends and possible macro headwinds.
Q2 2026 total revenues rose 7.3% to $106.1 billion; the prior-year quarter included $833 million in legacy litigation charges that did not recur
Full-year 2026 Adjusted EPS guidance raised to $7.90 to $8.10 from $7.30 to $7.50; GAAP diluted EPS guidance raised to $6.84 to $7.04 from $6.24 to $6.44
Cash flow from operations guidance raised to at least $11.5 billion from at least $9.5 billion; year-to-date operating cash flow was $10.6 billion
At its May 14, 2026 annual meeting, CVS Health stockholders approved a 2026 Incentive Compensation Plan that replaces the expiring 2017 plan, and elected all 13 director nominees to one-year terms. Stockholders also ratified Ernst & Young LLP as auditor for 2026 and approved the advisory say-on-pay proposal, while a stockholder proposal to lower the threshold for acting by written consent was not approved.
The 2026 Incentive Compensation Plan applies to awards granted after May 14, 2026; the vote was 1,006,709,390 for and 28,851,289 against.
The stockholder proposal on acting by written consent received 417,969,177 for and 617,361,014 against, and was not approved.
Shares present at the meeting totaled 1,142,802,406, constituting a quorum.
The advisory say-on-pay proposal was approved with 976,252,194 for and 59,088,923 against.
CVS Health reported first-quarter 2026 revenue of $100.4 billion, up 6.2% from a year earlier, with GAAP diluted EPS of $2.30 versus $1.41 and Adjusted EPS of $2.57 versus $2.25. The company raised its full-year 2026 guidance for GAAP diluted EPS, Adjusted EPS and cash flow from operations, while saying it is maintaining a cautious view for the rest of the year.
Q1 2026 total revenues $100.4 billion, up 6.2% from $94.6 billion; GAAP diluted EPS $2.30 vs. $1.41
Adjusted EPS $2.57 vs. $2.25; Health Care Benefits adjusted operating income rose to $3.0 billion from $2.0 billion
Full-year 2026 Adjusted EPS guidance raised to $7.30-$7.50 from $7.00-$7.20; GAAP diluted EPS guidance raised to $6.24-$6.44 from $5.94-$6.14
Full-year 2026 cash flow from operations guidance raised to at least $9.5 billion from at least $9.0 billion
CVS Health's Board elected John E. Gallina, former Elevance Health CFO, as a director effective March 19, 2026, and appointed him to the Audit Committee. The Board determined he is independent, and the filing describes him as an audit committee financial expert.
Board elected John E. Gallina, age 66, effective March 19, 2026; Board action taken March 18, 2026
Gallina served as Elevance Health CFO from June 2016 through November 1, 2023, and retired in May 2024
Appointed to the Audit Committee and designated an audit committee financial expert under SEC rules
Compensation as a non-employee director will be consistent with other directors, prorated for his start date
CVS Health reported fourth-quarter and full-year 2025 results, with revenue rising to $105.7 billion in the quarter and $402.1 billion for the year. Adjusted EPS fell to $1.09 in the quarter but rose to $6.75 for the full year, while full-year GAAP diluted EPS fell to $1.39 after a $5.7 billion goodwill impairment. The company confirmed its 2026 EPS guidance but lowered its cash flow from operations guidance to at least $9.0 billion from at least $10.0 billion.
Q4 2025 total revenues were $105.7 billion, up 8.2%, while adjusted EPS was $1.09 versus $1.19 a year earlier, primarily due to lower adjusted operating income in Health Care Benefits.
Full-year 2025 GAAP diluted EPS was $1.39 versus $3.66, reflecting a $5.7 billion goodwill impairment; full-year adjusted EPS rose to $6.75 from $5.42.
2026 guidance: GAAP diluted EPS of $5.94 to $6.14 and adjusted EPS of $7.00 to $7.20 were confirmed; cash flow from operations guidance was updated to at least $9.0 billion from at least $10.0 billion.
The results were released February 10, 2026 as Exhibit 99.1 and signed by CFO Brian O. Newman; 2025 cash flow from operations was $10.6 billion.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CVS Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →